The short- and long-term results of therapy of surgical diabetic foot patients

Introduction. The arterial limb threating is the leading cause of non-traumatic amputations in diabetic foot patients. The breakthrough in the treatment of this group of patients was the widespread introduction of transluminal balloon angioplasty (TLBA) of the arteries of the lower extremities.

Aim. To evaluate the results of the surgical treatment of the patients with diabetic neuro ischemic foot syndrome according the data of Government Center of Limb Salvation in 2022–2023 years.

Materials and methods. The study presents a retrospective analysis of medical documentations and the results of a survey one year after discharge from the hospital of 180 patients.

Results. The arterial limb threating is observed in equal frequency in both men with diabetes and women at a relatively young age (66.0 ± 12.8 years). The glycemic control in most patients is above the target values. Various groups of sugar-lowering drugs are widely used. More than a third of patients with CKD suffer from CKD with GFR less than 60 ml/min, however inSGLT-2 are used in slightly more than 15% of cases. The damages of the lower extremities arteries below the knee are observed in the most of cases. Every third patient has the occlusion/hemodynamically significant stenosis of the femoral and tibia arteries. The method of choosing revascularization is TLBA the lower extremities arteries without stenting, hybrid operations are performed in up to 10% of cases in the hospital. During the first year of follow up the 21.2% of the patients have recurrences of the ischemic tissue lesions of the feet including revascularization. The recurrences of the ischemic tissue lesions of the feet after surgical approach are revealed in 9% cases only. There are TLBA in all other cases. The mortality rate is 9.6 cases per 100 patients per year.

Conclusion. The patients after revascularization for the neuro-ischemic diabetic foot tissue loss and limb salvage remain at high risk of both mortality and recurrence of arterial limb threating in the early and delayed follow up.

1. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MА. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018;21(3):144–159. (In Russ.) https://doi.org/10.14341/DM9686.

2. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MА. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes Mellitus. 2021;24(3):204–221. (In Russ.) https://doi.org/10.14341/DM12759.

3. Galstyan GR, Vikulova OK, Isakov MA, Zheleznyakova AV, Serkov AA, Egorova DN et al. Trends in the epidemiology of diabetic foot and lower limb amputations in Russian Federation according to the Federal Diabetes Register (2013–2016). Diabetes Mellitus. 2018;21(3):170–177. (In Russ.) https://doi.org/10.14341/DM9688.

4. Galstyan GR, Tokmakova AYu, Egorova DN, Mitish VA, Paskhalova YuS, Antsiferov MB et al. Clinical guidelines for diagnosis and treatment of diabetic foot syndrome. Wounds and Wound Infections. The prof. B.M. Kostyuchenok Journal. 2015;2(3):63–83. (In Russ.) https://doi.org/10.17650/2408-9613-2015-2-3-63-83.

5. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625. https://doi.org/10.2337/diabetes.54.6.1615.

6. Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017;376(24):2367–2375. https://doi.org/10.1056/NEJMra1615439.

7. Ivanusa SYa, Risman BV, Shayakhmetov RE, Yanishevsky AV, Babenko MV, Shipilov PA. Computer planimetry as an objective control method for wound healing in diabetic foot syndrome. Bulletin of the Russian Military Medical Academy. 2023;25(2):239–248. (In Russ.) https://doi.org/10.17816/brmma321607.

8. Dedov II, Shestakova MV, Mayorov AY, Mokrysheva NG, Andreeva EN, Bezlepkina OB et al. Standards of Specialized Diabetes Care. Diabetes Mellitus. 2023;26(2 Suppl.):1–157. (In Russ.) https://doi.org/10.14341/DM13042.

9. Olutoye OO, Eriksson E, Menchaca AD, Kirsner RS, Tanaka R, Schultz G et al. Management of Acute Wounds - Expert Panel Consensus Statement. Adv Wound Care. 2024. https://doi.org/10.1089/wound.2023.0059.

10. Galstyan GR, Tokmakova AYu, Bondarenko ON, Sitkin II, Pryakhina KYu, Mitish VA, Doronina LP. Arterial diseases of lower extremities in diabetic patients: current state and prospects of therapy. Diabetes Mellitus. 2011;14(1):74–80. (In Russ.) https://doi.org/10.14341/2072-0351-6253.

11. Smart H, Sibbald RG, Goodman L, Ayello EA, Jaimangal R, Gregory JH et al. Wound Bed Preparation 2024: Delphi Consensus on Foot Ulcer Management in Resource-Limited Settings. Adv Skin Wound Care. 2024;37(4):180–196. https://doi.org/10.1097/asw.0000000000000120.

12. Efimov EV, Khoroshkevich AV. Features of wound process affected by diabetes mellitus. Wounds and Wound Infections. The prof. B.M. Kostyuchenok Journal. 2015;2(3):30–35. (In Russ.) https://doi.org/10.17650/2408-9613-2015-2-3-30-35.

13. Ponukumati AS, Krafcik BM, Newton L, Baribeau V, Mao J, Zhou W et al. Association between tissue loss type and amputation risk among Medicare patients with concomitant diabetes and peripheral arterial disease. J Vasc Surg. 2024:S0741-5214(24)01279-5. https://doi.org/10.1016/j.jvs.2024.06.019.

14. Bregovskiy VB, Karpova IA. Analysis of specialized care for patients with diabetic foot syndrome in St. Petersburg for 2010–2021. Diabetes Mellitus. 2022;25(5):477–484. (In Russ.) https://doi.org/10.14341/DM12914.

15. Fortington LV, Geertzen JH, van Netten JJ, Postema K, Rommers GM, Dijkstra PU. Short and long term mortality rates after a lower limb amputation. Eur J Vasc Endovasc Surg. 2013;46(1):124–131. https://doi.org/10.1016/j.ejvs.2013.03.024.

16. Fitridge R, Chuter V, Mills J, Hinchliffe R, Azuma N, Behrendt CA et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer. Diabetes Metab Res Rev. 2024;40(3):e3686. https://doi.org/10.1002/dmrr.3686.

17. Зеленина ТА, Ахмедова КС. Результаты лечения нейроишемической формы синдрома диабетической стопы по данным Городского Центра Спасения конечностей за 2022–2023 гг. В: Всероссийский междисциплинарный конгресс «Молчановские чтения – 2024»: сборник материалов конгресса. Санкт-Петербург, 15–16 марта 2024 г. СПб.: Военно-медицинская академия имени С.М. Кирова; 2024. С. 41–46. Режим доступа: https://www.elibrary.ru/jlfrbo.

18. Mitish VA, Paskhalova YuS, Ushakov AA, Slepnev SYu, Mishurinskaya EA. Role of disarticulation and guillotine amputation of the shin in the lower limb ischemic gangrene surgical treatment strategy. Wounds and Wound Infections. The prof. B.M. Kostyuchenok Journal. 2020;7(1):26–35. (In Russ.). https://doi.org/10.25199/2408-9613-2020-7-1-26-35.

19. Rümenapf G, Abilmona N, Morbach S, Sigl M. Peripheral Arterial Disease and the Diabetic Foot Syndrome: Neuropathy Makes the Difference! A Narrative Review. J Clin Med. 2024;13(7):2141. https://doi.org/10.3390/jcm13072141.

20. Borisov AG, Atmadzas AV, Atmadzas KA, Bogomolov DV, Gruzdev NN, Kuchay AA. Alternative conduit with contralateral lower extremity revascularization in infrainguinal reconstructions: risk factors for complications. Journal of New Medical Technologies. 2024;31(2):6–9. (In Russ.) https://doi.org/10.24412/1609-2163-2024-2-6-9.

21. Vorobikhina NV, Zelenina TA, Petrova TM. The effect of the method of surgical treatment of patients with purulent-necrotic forms of diabetic foot syndrome on the recurrence rate, the risk of repeated amputations and survival. Infektsii v Khirurgii. 2009;7(4):39–44. (In Russ.). Available at: https://elibrary.ru/unauul.

22. Twine CP, Kakkos SK, Aboyans V, Baumgartner I, Behrendt CA, Bellmunt-Montoya S et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. Eur J Vasc Endovasc Surg. 2023;65(5):627–689. https://doi.org/10.1016/j.ejvs.2023.03.042.

23. Ivanusa SYa, Risman BV, Yanishevsky AV, Shayakhmetov RE, Matveev IS. Treating diabetic foot syndrome at the general surgery clinic of the S.M. Kirov military medical academy. Medical Bulletin of the Main Military Clinical Hospital named after N.N. Burdenko. 2021;(3):20–29. (In Russ.) http://doi.org/10.53652/2782-1730-2021-2-3(5)-20-29.

24. Bazikian S, Pyun AJ, Zheng H, Padula W, Khan T, Ziegler K et al. Evaluating the impact of an interdisciplinary integrated limb preservation service operating concurrently with a single-specialty. J Foot Ankle Res. 2024;17(2):e12026. https://doi.org/10.1002/jfa2.12013.

25. Ivanusa SYa, Risman BV, Shaiakhmetov RE. Modern approaches in the surgical treatment of infectious complications of diabetic foot syndrome. Bulletin of the Russian Military Medical Academy. 2022;24(4):801–812. (In Russ.) https://doi.org/10.17816/brmma112591.

26. Bregovskiy VB, Demina AG, Karpova IA. Prevention of diabetic foot syndrome in patients with diabetes mellitus. Spravochnik Poliklinicheskogo Vracha. 2015;(4-5):30–33. (In Russ.) Available at: https://www.elibrary.ru/ubmfth.

27. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(39):4043–4140. https://doi.org/10.1093/eurheartj/ehad192.

28. SEC Working Group for the 2023 ESC Guidelines on cardiovascular disease in patients with diabetes and SEC Guidelines Committee. Comments on the 2023 ESC guidelines on cardiovascular disease in patients with diabetes. Rev Esp Cardiol (Engl Ed). 2024;77(3):196–200. https://doi.org/10.1016/j.rec.2023.11.005.

29. Kryukov EV, Kuchmin AN, Umanskaya EP, Nagorny MB, Shevelev AA. The main pathogenetic mechanisms of hypercoagulation in diabetes and the possibility of its drug. Bulletin of the Russian Military Medical Academy. 2021;23(2):165–174. (In Russ.). https://doi.org/10.17816/brmma64995.

30. Salukhov VV, Demidova TYu. Empagliflozin as a new strategy for managing outcomes in patients with type 2 diabetes mellitus and high cardiovascular risk. Diabetes Mellitus. 2016;19(6):494–510. (In Russ.) http://doi.org/10.14341/DM8216.